These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy. Zebertavage L; Schopf A; Nielsen M; Matthews J; Erbe AK; Aiken TJ; Katz S; Sun C; Witt CM; Rakhmilevich AL; Sondel PM J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731089 [No Abstract] [Full Text] [Related]
4. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Neal ZC; Imboden M; Rakhmilevich AL; Kim KM; Hank JA; Surfus J; Dixon JR; Lode HN; Reisfeld RA; Gillies SD; Sondel PM Cancer Immunol Immunother; 2004 Jan; 53(1):41-52. PubMed ID: 14504825 [TBL] [Abstract][Full Text] [Related]
5. Combining Immunocytokine and Bates PD; Rakhmilevich AL; Cho MM; Bouchlaka MN; Rao SL; Hales JM; Orentas RJ; Fry TJ; Gilles SD; Sondel PM; Capitini CM Front Immunol; 2021; 12():668307. PubMed ID: 34489927 [TBL] [Abstract][Full Text] [Related]
6. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106 [TBL] [Abstract][Full Text] [Related]
7. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2 Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307 [TBL] [Abstract][Full Text] [Related]
8. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745 [TBL] [Abstract][Full Text] [Related]
9. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape. Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337 [TBL] [Abstract][Full Text] [Related]
10. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331 [TBL] [Abstract][Full Text] [Related]
11. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models. Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484 [TBL] [Abstract][Full Text] [Related]
12. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457 [TBL] [Abstract][Full Text] [Related]
13. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells. Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I Front Immunol; 2024; 15():1382931. PubMed ID: 38736882 [TBL] [Abstract][Full Text] [Related]
14. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160 [TBL] [Abstract][Full Text] [Related]